Implantable Loop Recorders in Haemodialysis Patients

ISRCTN ISRCTN35846572
DOI https://doi.org/10.1186/ISRCTN35846572
Secondary identifying numbers 8356
Submission date
26/06/2017
Registration date
28/06/2017
Last edited
14/10/2022
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Circulatory System
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Background and study aims
Haemodialysis (also known as dialysis) is a therapy option for those whose kidneys do not work. This involves removing water and excess electrolytes (chemicals that maintain muscles) in a three to four hour session attached to the dialysis machine three times a week. It has been suggested that sudden cardiac death (SCD) contributes around 50% of cardiovascular mortality and up to 27% of all causes of death in haemodialysis patients. Identifying deaths that are truly sudden and cardiac can be challenging particularly in kidney failure and the true burden of arrhythmias and arrhythmic deaths in this population has been poorly studied. The aim of this study is to use a implantable loop recorder (ILR) device inserted into dialysis patients to continuously record their ECG (heart rhythm) and monitor cardiac events until death, battery life depletion of the ILR, explant of the device (for whatever reason in order to offer the longest follow up period of continuous ECG monitoring in this population to date.

Who can participate?
Adults aged 18 and older with end stage renal failure who are receiving regular dialysis

What does the study involve?
Participants who receive dialysis three times are week receive the ILR device. It is implanted in the left chest area. This device provides continuous ECG monitoring and data can be reviewed remotely by staff. Participants are trained on how to download their own data at each of their dialysis sessions. Device downloads are reviewed by researchers for any significant cardiac events. Participants are followed up until the end of the battery life, death or they require the ILR to be removed.

What are the possible benefits and risks of participating?
There are no notable benefits with participating, however it does help develop a better understanding of heat rhythm abnormalities for dialysis patients. There are potential risks of infection as well as pain/bruising associated with the implanting of the device.

Where is the study run from?
1. Southampton General Hospital (UK)
2. Queen Alexandra Hospital (UK)

When is the study starting and how long is it expected to run for?
July 2009 to December 2017

Who is funding the study?
Medtronic PLD (UK)

Who is the main contact?
Miss Elizabeth Greenwood
elizabeth.greenwood@uhs.nhs.uk

Contact information

Miss Bibi Greenwood
Public

CRM Research Office, Mailpoint 46
University Hospital Southampton NHS Foundation Trust – Southampton General Hospital
Tremona Road
Southampton
SO16 6YD
United Kingdom

Study information

Study design; Interventional; Design type: Device
Primary study designInterventional
Secondary study designNon randomised study
Study setting(s)Hospital
Study typeTreatment
Participant information sheet ISRCTN35846572_PIS_17Feb12_V1.47.pdf
Scientific titleCardio-Renal Arrhythmia Study in Haemodialysis patients using Implantable Loop Recorders (CRASH-ILR)
Study objectivesAn implantable loop recorder may identify whether certain patients who have end stage renal disease on dialysis are at an increased risk of cardiac arrhythmias.
Ethics approval(s)NRES Committee South Central – Hampshire A, 04/12/2009, ref: 09/H0502/121
Health condition(s) or problem(s) studiedSpecialty: Cardiovascular disease, Primary sub-specialty: Arrhythmia
InterventionParticipants are recruited from a single tertiary nephrology centre in the UK and all were receiving haemodialysis three times a week.

Participants receive the intervention of the having an implantable loop recorder (ILR) device (Reveal XT®) implanted in the left parasternal region. ILRs are routinely used in clinical practice for the diagnosis of arrhythmias, have around a 3 year battery life and the data they capture can be transmitted using a secure website from a telephone landline or mobile to a computer. ILRs are cardiac devices which provide continuous ECG monitoring & this data can be transmitted regularly for review remotely. Device programming is standardised to include automatic detection of brady/tachy arrhythmias and patient activated recordings. Participants are trained on how to transmit data from their device at each dialysis session via the remote monitoring CareLink system (Medtronic). Every device download (following successful transmission) is manually scrutinised independently by two members of the research team.

Participants are followed up was from their day of implantation to death, explant or end of battery life of ILR depending on whichever came first.

Any cardiac event considered to be of clinical significance was relayed to the nephrologist involved in the patient’s care.
Intervention typeOther
Primary outcome measure1. Sudden cardiac death (SCD) is measured using continuous ECG data downloaded from the ILR device. In addition to clinical information and post mortem examination where performed.
2. Implantation of pacing device is measured by reporting the number of pacemakers or defibrillators that were implanted during the course of the study.
Secondary outcome measuresDevelopment of significant arrhythmia necessitating medical intervention is measured using continuous ECG data from the ILR device.
Overall study start date13/07/2009
Completion date31/12/2017

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexBoth
Target number of participantsPlanned Sample Size: 30; UK Sample Size: 30
Total final enrolment30
Key inclusion criteria1. End Stage Renal Failure (ESRF)
2. Received regular haemodialysis for a minimum of 90 days prior to study entry and is expected to continue with haemodialysis indefinitely or until renal transplant
3. At least 18 years of age
4. Willing and able to comply with investigational plan and willing to remain available for follow-up through to study closure
5. Willing and able to sign/date the study informed consent
Key exclusion criteria1. Myocardial infarction in preceding 40 days prior to enrolment
2. Already implanted with a cardiac device, such as pacemaker, defibrillator or implantable loop recorder (ILR)
3. Life expectancy less than one year in the opinion of an Investigator
4. Enrolled in another research study
5. Expected to have poor compliance with the study protocol
6. Pregnancy or breastfeeding
7. Haemodialysis via leftsided tunnelled central venous catheter
8. Expected to require a thoracic magnetic resonance image (MRI)
Date of first enrolment30/08/2011
Date of final enrolment23/10/2014

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centres

Southampton General Hospital (Lead Site)
CRM Research Office
Mailpoint 46
Tremona Road
Southampton
SO16 6YD
United Kingdom
Queen Alexandra Hospital
Cardiology Research
Southwick Hill Road
Cosham
Portsmouth
PO6 3LY
United Kingdom

Sponsor information

Queen Alexandra Hospital
Hospital/treatment centre

Portsmouth Hospitals NHS Trust
De La Court House
Southwick Hill Road
Portsmouth
PO6 3LY
England
United Kingdom

ROR logo "ROR" https://ror.org/04rha3g10

Funders

Funder type

Government

Medtronic Ltd

No information available

Results and Publications

Intention to publish date01/09/2017
Individual participant data (IPD) Intention to shareYes
IPD sharing plan summaryOther
Publication and dissemination planPlanned publication in a peer reviewed journal. An abstract summarising interim results was presented at AHA Conference, Texas, Dallas 2013 summarising the findings after 188,880 hours of continuous monitoring.
IPD sharing planThe datasets generated and/or analysed during the current study during this study will be included in the subsequent results publication.

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Participant information sheet version V1.47 17/02/2012 28/06/2017 No Yes
Participant information sheet version V1.47 17/02/2012 12/07/2017 No Yes
Results article results 14/12/2017 Yes No
Protocol file version 1.5 15/08/2014 14/10/2022 No No

Additional files

ISRCTN35846572_PIS_17Feb12_V1.47.pdf
Uploaded 28/06/2017
ISRCTN35846572_PIS_17Feb12_V1.47.pdf
Uploaded 12/07/2017
ISRCTN35846572_PROTOCOL_V1.5_15Aug14.pdf

Editorial Notes

14/10/2022: Protocol uploaded (not peer reviewed) and total final enrolment added.
09/03/2018: Publication reference added.
24/10/2017: The registration of this study was requested through the NIHR Portfolio. The trialist confirmed the recruitment start and end dates.
22/09/2017: Internal review.
20/07/2017: Internal review
12/07/2017: Participant Information Sheets uploaded.